© Drug Hunter Inc. 2018-2023
Home > “PROTAC 6”
IAP-based selective RIPK2 degrader
prolonged PD w/ 0.15 mpk SC Q3D dosing
E3 binder switch and property-based opt.
Commun. Biol., Mar. 20, 2020
GlaxoSmithKline, Stevenage, UK / PMCC
“PROTAC 6” (GlaxoSmithKline (GSK) IAP-based selective RIPK2 degrader with prolonged in vivo PD)
Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more.
Interested in learning more? Submit this form to request a trial.
Molecules of the Month
Molecule of the Year